July 8, 2016 4:37pm
… Downside victims: BioLife Solutions (BLFS), bluebird bio (BLUE), Capricor (CAPR), Juno (JUNO), Kite Pharma (KITE), and Cellectis SA (CLLS)
While Bellicum (BLCM), Intrexon (XON), and Mesoblast (MESO) bounced back as the iShares Nasdaq Biotechnology ETF (IBB) trended up +1.23%
… Investors should be breathing a sigh of relief
My pre-open indications – 3 hits and 3 miss:
Do you care what happened today, you should … because it has implications to Monday's sector activity?
Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed more than 1% higher Friday, more than recovering their post-Brexit losses, after a surprisingly large beat on the June jobs report headline figure.
The NASDAQ closed UP +79.95 or +1.64% to 4,956.76 and the DOW closed UP +250.86 or +1.40% to 18,146.74.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 22/19 and 2 flats;
- The mid-day was positive with an A/DL of 29/12 and 3 flats;
- The closing bell was positive with A/DL of 29/13 and 1 flat;
Henry’omics:
The title of the closing bell post speaks for itself …
- Such a vacation week, I am still not having …
The SCGT&RT sector opened positive, stayed positive at the mid-day and closed positive.
- The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded near 13.3, a one-month low.
There are so many uncertainties as financial results/earnings are being prepared for announcement! The issue will be spending, ATM usage and the lack of capital market access.
My pet peeve:
High-frequency trading accounted for 49% of July's daily trading volume of about 7 billion shares <according to TABB Group>.
- During the peak levels of high-frequency trading in 2009, about 61% of 9.8 billion of average daily shares traded were executed by high-frequency traders.
Review my fear gauge or the CBOE Volatility Index (VIX):
- Friday traded below 13.3;
- Thursday traded near 15.89;
- Wednesday traded above 17;
- Tuesday near 16;
- Monday was a holiday;
- Last, Friday traded near 14;
Today’s Bottom Line:
As I stated in the title, a sigh of relief was breathed as the sector bounced back … from JUNO’s news.
- Also be VERY thankful of the macroeconomics news i.e. jobs report figures
My pre-open indications – 3 hits and 3 miss:
- Applied Genetic Technologies (AGTC) closed UP +$0.24 – miss;
- Bellicum Pharma (BLCM) closed UP +$0.25 – miss;
- bluebird bio (BLUE) closed DOWN -$0.08 – hit;
- Cellectis SA (CLLS) closed DOWN -$1.57 – miss;
- Juno Therapeutics (JUNO) closed DOWN -$13.01 – hit;
- Kite Pharma (KITE) closed DOWN -$3.57 – hit;
Largest decliners:
- Juno Therapeutics (JUNO) -31.87%;
- Kite Pharma (KITE) -6.85%;
- BioLife Solutions (BLFS) -6.13%
- Cellectis SA (CLLS) -5.88%;
- International Stem Cell (ISCO) -5.74%;
Advancers:
- Histogenics (HSGX) +12.80% or +$0.21 ;
- Pluristem (PSTI) +7.41% or +$0.10;
- Adverum (ADVM) +5.96% or +$0.19;
- AxoGen (AXGN) +5.67%;
- Northwest Bio (NWBO) +5.56% or +$0.0278;
Flat:
- ReNeuron (RENE.L) at $2.625;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
